Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Conditions
Brief summary
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.
Detailed description
PRIMARY OBJECTIVE: I. To compare event-free survival (EFS) in participants with high-risk resectable melanoma randomized to neoadjuvant pembrolizumab (MK-3475) with participants randomized to adjuvant pembrolizumab (MK-3475). SECONDARY OBJECTIVES: I. To assess the frequency and severity of toxicities on each of the arms. II. To compare between arms overall survival (OS), disease control at 24 weeks, locoregional control in the surgical site(s), and total number of pembrolizumab (MK-3475) doses received. III. On the neoadjuvant arm, to estimate the pathologic response rate, the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response rate (confirmed and unconfirmed complete response \[CR\] and partial response \[PR\]), and the immune-related (i)RECIST response rate (confirmed and unconfirmed CR and PR), before surgical resection; to compare definitions of pathologic partial response; and to evaluate the association between pathologic response and EFS and OS. IV. To describe the proportion of participants on each arm who received the surgery planned at randomization. ADDITIONAL OBJECTIVE: I. To bank tumor tissue and whole blood in anticipation of future correlative studies in this participant population. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Within 17 days (preferably within 14 days) days after surgical resection, patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study, and magnetic resonance imaging (MRI) or computers tomography (CT) on study. ARM II: Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgical resection within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study. After completion of study treatment, patients are followed up at 3 and 12 weeks, then every 3 months for 2 years, every 6 months for 3 years, then every 12 months for up to 10 years.
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of blood
PROCEDUREComputed Tomography
Undergo CT
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
BIOLOGICALPembrolizumab
Given IV
PROCEDURETherapeutic Conventional Surgery
Undergo surgery
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* STEP 1 REGISTRATION (RANDOMIZATION): Patients must have clinically detectable stage III (clinically detectable N1b, N1c, N2b, N2c, N3b and N3c) or stage IV resectable melanoma. Patients with melanoma of mucosal or acral origin are eligible. Patients with melanoma of uveal origin are not eligible. Patients with a history of brain metastases are not eligible. Clinically detectable is defined as disease that is apparent and measurable via physical examination or radiographic imaging. * STEP 1 REGISTRATION (RANDOMIZATION): Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site. Nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by hematoxylin (H) \& eosin (E) stained slides. * STEP 1 REGISTRATION (RANDOMIZATION): Patients with multiple regional nodal basin involvement are eligible. Gross or microscopic extracapsular nodal extension is permitted. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must have histologically proven stage IIIB or higher. This would entail pathologic confirmation beyond the primary or initial diagnosis of melanoma involving fine needle aspiration cytology or biopsy confirmation of any N-category or M-category resectable site. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have received previous neoadjuvant treatment for their melanoma. Patients may have received prior non-immunotherapy adjuvant therapy. Patients must not have had prior immunotherapy including, but not limited to ipilimumab, interferon alfa-2b, high dose interleukin (IL)-2, pegylated-interferon (PEG-IFN), anti-PD-1, anti-PD-L1 intra-tumoral, or vaccine therapies. Patients must not be planning to receive any of the prohibited therapies during treatment phases on the study. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not be planning to receive concomitant other biologic therapy, hormonal therapy, other chemotherapy, surgery, while on protocol therapy. * STEP 1 REGISTRATION (RANDOMIZATION): Patients may have received prior radiation therapy, including after prior surgical resection. All adverse events associated with prior surgery and radiation therapy must have resolved to =\< grade 1 prior to randomization. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must be \>= 18 years of age * STEP 1 REGISTRATION (RANDOMIZATION): All patients must have disease status documented by a complete physical examination and imaging studies within 42 days prior to randomization. Imaging studies must include a CT of the chest, abdomen and pelvis with intravenous contrast (unless contraindicated). For patients with melanoma arising from the head and neck, dedicated neck imaging (CT with intravenous contrast is required. If the patient has unknown primary with disease in the axilla, neck imaging is required CT imaging must be done with intravenous contrast if there are no contraindications for it. Extremity melanomas must be imaged using CT with intravenous contrast or MRI with and without gadolinium * Note: PET-CT scans are NOT acceptable to establish eligibility. Non-iodinated CT scans that are part of common PET-CT imaging protocols do not provide contrast for difficult to ascertain areas such as the neck and liver, and do not provide enough CT detail to perform appropriate RECIST 1.1 measurements. As such, a PET-CT with non-contrast CT or non-diagnostic quality CT images is considered insufficient for the detection of melanoma. * STEP 1 REGISTRATION (RANDOMIZATION): All patients must have a CT or magnetic resonance imaging (MRI) of the brain within 42 days prior to randomization. The brain CT or MRI should be performed with intravenous contrast (unless contraindicated). * STEP 1 REGISTRATION (RANDOMIZATION): Absolute neutrophil count (ANC) \>= 1,500/microliter (mcL) (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Platelets \>= 100,000/mcL (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Hemoglobin \>= 10 g/dL (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Total bilirubin =\< 1.5 x institutional upper limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total bilirubin \< 3.0 mg/dL) (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 2 x IULN (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Alkaline phosphatase =\< 2 x IULN (within 42 days prior to randomization). * STEP 1 REGISTRATION (RANDOMIZATION): Patients must have lactate dehydrogenase (LDH) performed within 42 days prior to randomization. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must have adequate renal function as evidenced by calculated creatinine clearance \> 30 mL/min. The creatinine level (mg/dL) used in the calculation must be obtained within 42 days prior to randomization. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must have Zubrod performance status =\< 2. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have an active infection requiring systemic therapy. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have received live vaccines within 42 days prior to randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed. * NOTE: The COVID-19 vaccines (currently available and those in the pipeline for FDA emergency use authorization or FDA approval) do not contain live virus, and therefore, COVID-19 vaccination does not affect or preclude eligibility for the S1801 trial. For patients who have undergone lymphadenectomy, vaccines should be delivered to a limb with an intact lymph node basin (Sentinel lymph node biopsy in a limb is acceptable). The vaccine should not be administered in a limb that has undergone lymphadenectomy. * STEP 1 REGISTRATION (RANDOMIZATION): Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to randomization: stable and adequate CD4 counts (\>= 350 mm\^3), and serum HIV viral load of \< 25,000 IU/ml. Patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Note: No testing for hepatitis B and hepatitis C is required unless mandated by local health authority. * STEP 1 REGISTRATION (RANDOMIZATION): Prior malignancy is allowed providing it does not require concurrent therapy. * STEP 1 REGISTRATION (RANDOMIZATION): Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to randomization. Women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Patients must not be pregnant or nursing due to unknown teratogenic side effects. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must be deemed medically fit to undergo surgery by the treating medical/surgical team. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must be willing to submit the following surgical specimens: either all tissue blocks from the surgical specimen or two slides per block (\[1\] hematoxylin and eosin \[H\&E\] slide and \[1\] unstained slide OR \[2\] unstained slides if H\&E stained slides cannot be provided). * STEP 1 REGISTRATION (RANDOMIZATION): Patients must be offered the opportunity to participate in specimen banking. * STEP 1 REGISTRATION (RANDOMIZATION): Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines. * STEP 1 REGISTRATION (RANDOMIZATION): As a part of the Oncology Patient Enrollment Network (OPEN) randomization process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system. * STEP 2 REGISTRATION (SURGERY): Patients randomized to arm 2 (neoadjuvant arm) must be willing to submit tissue to determine pathologic response regardless of number of pre-operative doses of pembrolizumab (MK-3475) received. Determination of pathologic response cannot be done on less than the full surgical specimen. * STEP 2 REGISTRATION (SURGERY): Patients must have disease assessments by CT chest/abdomen/pelvis with IV contrast, and neck CT with IV contrast if primary head and neck melanoma, performed within 42 days (and no more than 49 days) before the planned date of surgery. MRI combined with non-contrast CT is an acceptable alternative for patients with CT contrast allergy, but imaging must encompass total body. * STEP 2 REGISTRATION (SURGERY): Patients must register to step 2 within 17 days prior to planned date of surgery. * STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients must have undergone surgery prior to Step 3 registration. The Step 2 surgery must have completely resected their melanoma. * Patients with gross positive residual disease following surgery do not qualify as having disease-free status, and, therefore, such patients are not eligible to register for adjuvant therapy. * Patients with microscopic residual disease (i.e., positive margins) can be treated with re-excision or radiation, per site discretion, to render the patient disease-free prior to registration of adjuvant therapy. * Disease-free status must be documented by a complete physical examination and radiographic imaging studies within 42 days prior to Step 3 registration. Imaging studies must include a CT of the chest, abdomen, and pelvis (unless contraindicated). Extremity melanomas must be imaged using CT with intravenous contrast or MRI with and without gadolinium. CT imaging must be done with intravenous contrast if there are no contraindications for it. * For patients with melanoma arising from the head and neck, dedicated neck imaging (CT with IV contrast, unless contraindicated) is required. * If the patient has had unknown primary with disease in the axilla, neck imaging is required to assure the region is clear of cancer. * Any other clinically indicated imaging studies if performed (e.g., bone scan) must show no evidence of disease. * STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients must be registered to step 3 no more than 84 days after date of surgery. * STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients with R0 or R1 resections must have disease-free status documented by a complete physical examination and imaging studies within 42 days prior to step 3 registration. These patients must have disease assessments by CT chest/abdomen/pelvis with IV contrast, and neck CT with IV contrast if primary head and neck melanoma. MRI combined with non-contrast CT is an acceptable alternative for patients with CT contrast allergy, but imaging must encompass total body. * STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients with R2 resections are not eligible for step 3 and must be removed from study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Two-Year Event-Free Survival Rate | 2 years | Event-free survival (EFS) is measured from date of randomization to date of first: documentation of progression that render participant unable to receive planned protocol surgery, off protocol therapy for any reason without subsequent protocol surgery, failure to begin adjuvant therapy within 84 days after surgery, relapse after surgery or death due to any cause. Participants last known to be alive and event-free are censored at date of last contact. All events that occurred before the start of adjuvant therapy were assigned an event date of 84 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Duration of treatment and follow-up until relapse, death, or 3.5 years post randomization. | Only adverse events that are possibly, probably or definitely related to study drug are reported. |
| Two-Year Overall Survival Rate | 2 years | Overall survival (OS) is measured from date of randomization to date of death due to any cause. Participants known to be alive are censored at date of last contact. |
| Response Rate | 2 years | On the neoadjuvant arm, the response rate was assessed after neoadjuvant therapy and before surgical resection. The response rate includes both complete response (CR) and partial response (PR). CR is defined as complete disappearance of all target and non-target lesions, no new lesions, and no disease related symptoms. PR is defined as greater than or equal to 30% decrease under baseline of the sum of all appropriate diameters of all target measurable lesions, no unequivocal progression or non-measurable disease, and no new lesions. The best response rate is calculated from the sequence of objective statuses. CR is defined as two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. PR is defined as two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration, but not qualifying as CR. |
| Number of Participants Receiving Surgery | 2.5 years | To determine the number of participants on each arm who received the surgery planned at randomization. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSapna P Patel
SWOG Cancer Research Network
Participant flow
Pre-assignment details
Three hundred forty-five participants were assessed for eligibility. Thirty-two participants were deemed ineligible for either not having measurable disease, per RECIST criteria (27 participants), or having an ineligible disease stage (5). The remaining 313 eligible participants were randomized.
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Adjuvant Pembrolizumab) Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
Biospecimen Collection: Undergo collection of blood
Computed Tomography: Undergo CT
Magnetic Resonance Imaging: Undergo MRI
Pembrolizumab: Given IV
Therapeutic Conventional Surgery: Undergo surgery | 159 |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
Biospecimen Collection: Undergo collection of blood
Computed Tomography: Undergo CT
Magnetic Resonance Imaging: Undergo MRI
Pembrolizumab: Given IV
Therapeutic Conventional Surgery: Undergo surgery | 154 |
| Total | 313 |
Baseline characteristics
| Characteristic | Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Total | Arm I (Adjuvant Pembrolizumab) |
|---|---|---|---|
| Age, Continuous | 64 years | 64 years | 62 years |
| BRAF Mutation Status Mutated | 41 Participants | 79 Participants | 38 Participants |
| BRAF Mutation Status Unknown | 51 Participants | 108 Participants | 57 Participants |
| BRAF Mutation Status Wild-type | 62 Participants | 126 Participants | 64 Participants |
| Disease Stage IIIB | 62 Participants | 126 Participants | 64 Participants |
| Disease Stage IIIC | 69 Participants | 143 Participants | 74 Participants |
| Disease Stage IIID | 9 Participants | 19 Participants | 10 Participants |
| Disease Stage IV | 14 Participants | 25 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 13 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 136 Participants | 287 Participants | 151 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 9 Participants | 13 Participants | 4 Participants |
| LDH Level High | 22 Participants | 43 Participants | 21 Participants |
| LDH Level Low or Normal | 132 Participants | 270 Participants | 138 Participants |
| Previous BRAF and MEK Adjuvant Therapy No | 151 Participants | 309 Participants | 158 Participants |
| Previous BRAF and MEK Adjuvant Therapy Yes | 3 Participants | 4 Participants | 1 Participants |
| Previous Radiotherapy No | 152 Participants | 310 Participants | 158 Participants |
| Previous Radiotherapy Yes | 2 Participants | 3 Participants | 1 Participants |
| Primary Melanoma Subtype Acral | 4 Participants | 9 Participants | 5 Participants |
| Primary Melanoma Subtype Cutaneous or Unknown | 143 Participants | 296 Participants | 153 Participants |
| Primary Melanoma Subtype Missing/Not Reported | 3 Participants | 4 Participants | 1 Participants |
| Primary Melanoma Subtype Mucosal | 4 Participants | 4 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 10 Participants | 14 Participants | 4 Participants |
| Race (NIH/OMB) White | 141 Participants | 291 Participants | 150 Participants |
| Sex: Female, Male Female | 62 Participants | 110 Participants | 48 Participants |
| Sex: Female, Male Male | 92 Participants | 203 Participants | 111 Participants |
| Ulceration Missing/Not Reported | 2 Participants | 2 Participants | 0 Participants |
| Ulceration No | 50 Participants | 108 Participants | 58 Participants |
| Ulceration Unknown | 46 Participants | 101 Participants | 55 Participants |
| Ulceration Yes | 56 Participants | 102 Participants | 46 Participants |
| Zubrod Performance Status Score 0 | 113 Participants | 238 Participants | 125 Participants |
| Zubrod Performance Status Score 1 | 39 Participants | 72 Participants | 33 Participants |
| Zubrod Performance Status Score 2 | 1 Participants | 1 Participants | 0 Participants |
| Zubrod Performance Status Score Missing/Not Reported | 1 Participants | 2 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 22 / 159 | 14 / 154 |
| other Total, other adverse events | 132 / 141 | 148 / 152 |
| serious Total, serious adverse events | 33 / 141 | 34 / 152 |
Outcome results
Primary
Two-Year Event-Free Survival Rate
Event-free survival (EFS) is measured from date of randomization to date of first: documentation of progression that render participant unable to receive planned protocol surgery, off protocol therapy for any reason without subsequent protocol surgery, failure to begin adjuvant therapy within 84 days after surgery, relapse after surgery or death due to any cause. Participants last known to be alive and event-free are censored at date of last contact. All events that occurred before the start of adjuvant therapy were assigned an event date of 84 days.
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Adjuvant Pembrolizumab) | Two-Year Event-Free Survival Rate | 49 percentage of participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Two-Year Event-Free Survival Rate | 72 percentage of participants |
p-value: 0.004Log Rank
Secondary
Number of Participants Receiving Surgery
To determine the number of participants on each arm who received the surgery planned at randomization.
Time frame: 2.5 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Adjuvant Pembrolizumab) | Number of Participants Receiving Surgery | 151 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants Receiving Surgery | 127 Participants |
Secondary
Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Time frame: Duration of treatment and follow-up until relapse, death, or 3.5 years post randomization.
Population: Eligible participants that received protocol treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Diarrhea | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Alanine aminotransferase increased | 3 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Alkaline phosphatase increased | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Anemia | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Arthralgia | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Arthritis | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Aspartate aminotransferase increased | 2 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Blood and lymphatic system disorders - Other, spec | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cardiac disorders - Other, specify | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cardiac troponin I increased | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Chest wall pain | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cognitive disturbance | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Colitis | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Dehydration | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Adrenal insufficiency | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Electrocardiogram QT corrected interval prolonged | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fall | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fatigue | 2 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fever | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Gallbladder infection | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Headache | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hematoma | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hepatobiliary disorders - Other, specify | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hyperglycemia | 3 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypertension | 2 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypokalemia | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hyponatremia | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypothyroidism | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Infections and infestations - Other, specify | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Lung infection | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Lymphocyte count decreased | 3 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Metabolism and nutrition disorders - Other, specif | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myalgia | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myocarditis | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myositis | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Nausea | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Neutrophil count decreased | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Platelet count decreased | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Pneumonitis | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Pruritus | 2 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Rash maculo-papular | 4 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Respiratory failure | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Sepsis | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Seroma | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Skin and subcutaneous tissue disorders - Other, sp | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Skin infection | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Small intestinal obstruction | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Soft tissue infection | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Stroke | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Surgical and medical procedures - Other, specify | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Syncope | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Thromboembolic event | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Urinary tract infection | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Vomiting | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | White blood cell decreased | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Wound dehiscence | 0 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Febrile neutropenia | 1 Participants |
| Arm I (Adjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Wound infection | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Infections and infestations - Other, specify | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Adrenal insufficiency | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Vomiting | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Alanine aminotransferase increased | 5 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Lung infection | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Alkaline phosphatase increased | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Seroma | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Anemia | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Lymphocyte count decreased | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Arthralgia | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Syncope | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Arthritis | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Metabolism and nutrition disorders - Other, specif | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Aspartate aminotransferase increased | 4 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Skin and subcutaneous tissue disorders - Other, sp | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Blood and lymphatic system disorders - Other, spec | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myalgia | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cardiac disorders - Other, specify | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Wound dehiscence | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cardiac troponin I increased | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myocarditis | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Chest wall pain | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Skin infection | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Cognitive disturbance | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Myositis | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Colitis | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Thromboembolic event | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Dehydration | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Nausea | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Diarrhea | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Small intestinal obstruction | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Electrocardiogram QT corrected interval prolonged | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Neutrophil count decreased | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fall | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | White blood cell decreased | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fatigue | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Febrile neutropenia | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Platelet count decreased | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Fever | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Soft tissue infection | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Gallbladder infection | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Pneumonitis | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Headache | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Urinary tract infection | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hematoma | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Pruritus | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hepatobiliary disorders - Other, specify | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Stroke | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hyperglycemia | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Rash maculo-papular | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypertension | 3 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Wound infection | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypokalemia | 2 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Respiratory failure | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hyponatremia | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Surgical and medical procedures - Other, specify | 1 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Hypothyroidism | 0 Participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Sepsis | 1 Participants |
Secondary
Response Rate
On the neoadjuvant arm, the response rate was assessed after neoadjuvant therapy and before surgical resection. The response rate includes both complete response (CR) and partial response (PR). CR is defined as complete disappearance of all target and non-target lesions, no new lesions, and no disease related symptoms. PR is defined as greater than or equal to 30% decrease under baseline of the sum of all appropriate diameters of all target measurable lesions, no unequivocal progression or non-measurable disease, and no new lesions. The best response rate is calculated from the sequence of objective statuses. CR is defined as two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. PR is defined as two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration, but not qualifying as CR.
Time frame: 2 years
Secondary
Two-Year Overall Survival Rate
Overall survival (OS) is measured from date of randomization to date of death due to any cause. Participants known to be alive are censored at date of last contact.
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Adjuvant Pembrolizumab) | Two-Year Overall Survival Rate | 79 percentage of participants |
| Arm II (Adjuvant and Neoadjuvant Pembrolizumab) | Two-Year Overall Survival Rate | 87 percentage of participants |